Jimin He

Dr. Jimin He

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
YJYao Jiang
Yao Jiang
JHJimin He
Jimin He
YGYongcan Guo
Yongcan Guo
HTHualin Tao
Hualin Tao
FPFei Pu
Fei Pu
YLYiqin Li
Yiqin Li

29 November 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YJYao Jiang
Yao Jiang
JHJimin He
Jimin He
YLYiqin Li
Yiqin Li
YGYongcan Guo
Yongcan Guo
HTHualin Tao
Hualin Tao
Background. Recently, the role of microRNAs (miRNAs) in diagnosing cancer has been attracted increasing attention. However, few miRNAs have been applied in clinical practice. The purpose of this study was to evaluate the diagnostic efficacy of miRNAs for hepatocellular carcinoma (HCC) at early stages clinically. Methods. A literature search was carried out using PubMed, Web of Science, and EMBASE databases. We explored the diagnostic value of miRNAs in distinguishing HCC from healthy individuals. The quality assessment was performed in Review Manager 5.3 software. The overall sensitivity and specificity and 95% confidence intervals (CIs) were obtained with random-effects models through Stata 14.0 software. And heterogeneity was assessed using Q test and I2 statistics. Meta-regression and subgroup analyses were conducted based on the sample, nation, quality of studies, and miRNA profiling. The publication bias was evaluated through Deeks’ funnel plot. Results. A total of 34 studies, involving in 2747 HCC patients and 2053 healthy individuals, met the inclusion criteria in the 33 included literature studies. In the summary receiver operating characteristic (sROC) curve, AUC was 0.92 (95% CI, 0.90–0.94), with 0.84 (95% CI, 0.79–0.88) sensitivity and 0.87 (95% CI, 0.83–0.90) specificity. There was no publication bias (P=0.48). Conclusion. miRNAs in vivo can be acted as a potential diagnostic biomarker for HCC, which can facilitate the early diagnosis of HCC in clinical practice.

7 September 2016 in Oncology Letters
Verified
Journal Article
Open access
PDF file
JHJimin He
Jimin He
XGXiaoxin Guo
Xiaoxin Guo
LSLinlin Sun
Linlin Sun
KWKuhao Wang
Kuhao Wang
HYHaiying Yao
Haiying Yao
Wilms' tumor (WT) is a common kidney cancer. To date, the expression of genes [transcription factors (TFs), target genes and host genes] and microRNAs (miRNAs/miRs) in WTs has captured the attention of biologists, while the regulatory association between the genes and miRNAs remains unclear. In the present study, TFs, miRNAs, target genes and host genes were considered as key factors in the construction of three levels of regulatory networks, namely, the differentially-expressed network, the related network and the global network. The four factors had three types of association, including the regulation of miRNAs by TFs, the targeting of the target genes by miRNAs and the location of miRNAs at host genes. The differentially-expressed network is the most important of the three networks, and only involves the differentially-expressed genes and miRNAs; with the exception of host genes, those elements all behave abnormally when a WT occurs, which suggests that the differentially-expressed network can accurately reveal the pathogenesis of WTs. E2F3, for example, is overexpressed in WTs, and it regulates hsa-let-7a, hsa-let-7a-1, hsa-miR-106b, among others. Meanwhile, E2F3 is targeted by hsa-miR-106b, hsa-miR-17 and hsa-miR-20a. If the regulatory network can be used to adjust those factors to a normal level, there may be a chance to cure patients with WTs. WT-associated factors were placed into the related network; this network is useful for understanding the regulatory pathways of genes and miRNA in WTs. The networks provide a novel perspective in order to study the inner interactions of genes and miRNAs. The present study provides authoritative data and regulatory pathway analysis in order to partially elucidate the pathogenesis of WT, and thus supplies biologists with a basis for future research.

13 January 2026 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
YJYao Jiang
Yao Jiang
QLQin Li
Qin Li
DHDa Hu
Da Hu
HLHuaqiang Liao
Huaqiang Liao
SCShu Chen
Shu Chen
JHJimin He
Jimin He
Objective: Ischemic stroke (IS) with hyperuricemia (HUA) correlates with poor outcomes, yet the shared pathophysiological traits remain unclear. This study examined metabolic parameters in HUA-IS comorbidity and developed an optimal interpretable Clinlabomics model for risk assessment. Methods: A total of 2,164 IS patients and 2,459 healthy controls (HCs) were retrospectively enrolled. Participants were divided into four groups: HUA-IS (comorbidity, n=1,082), non-HUA IS (n=1,082), HUA HCs (n=1,314), non-HUA HCs (n=1,145); the latter three were defined as the non-comorbidity group. After 1:1 propensity score matching (PSM), 1,031 cases were matched in each group. Ten metabolic parameters were analyzed: serum uric acid at admission (SUA_admission), SUA on the third day of hospitalization (SUA_3d), triglyceride-glucose index (TyG), triglyceride (TG), high-density lipoprotein cholesterol (HDL−C), atherogenic index of plasma (AIP), atherogenic coefficient (AC), lipoprotein combine index (LCI), Castelli’s risk index I (CRI-I), and Castelli’s risk index II (CRI-II). Univariate/multivariate logistic regression, quartile-based logistic regression, and restricted cubic spline (RCS) analysis were used to explore parameters - comorbidity associations. Post-PSM data were split 7:3 into training/testing sets, least absolute shrinkage and selection operator (LASSO) regression selected features, and 11 machine learning algorithms developed Clinlabomics models. Additionally, the optimal model was validated in the testing set and an independent validation set. Results: After PSM, multivariate logistic regression identified AIP as the strongest risk factor (OR = 2.74, 95%CI: 1.80-4.19). The Q4 of TyG, TG, AIP, and LCI elevated comorbidity risk ( P < 0.05). Besides, RCS showed nonlinear association of LCI with comorbidity ( P < 0.05). The Recursive Partitioning and Regression Trees (rpart)-based Clinlabomics model exhibited favorable performance with F1-score, accuracy (ACC), and area under the curve (AUC) of 0.960, 0.960, and 0.986. At optimal hyperparameter (cp=0.0017), the model achieved AUCs of 0.987 (95%CI: 0.982-0.993), 0.955 (95%CI: 0.939-0.972), and 0.957 (95%CI: 0.915-0.999) in the training, testing, and validation datasets, respectively, correctly identifying 87.7% non-comorbidity and 98.0% comorbidity patients in validation. SHapley Additive exPlanations (SHAP) analysis identified UA_admission, UA_3d, TyG, TG, AIP and LCI as key metabolic indicators. Conclusion: TyG, TG, AIP, and LCI were critical metabolic parameters for HUA-IS comorbidity, which warrant heightened attention in future comorbidity research.

27 August 2021 in Computational and Mathematical Methods in Medicine
Verified
Journal Article
Open access
PDF file
JHJimin He
Jimin He
CZChun Zeng
Chun Zeng
YLYong Long
Yong Long
Glioma is a frequently seen primary malignant intracranial tumor, characterized by poor prognosis. The study is aimed at constructing a prognostic model for risk stratification in patients suffering from glioma. Weighted gene coexpression network analysis (WGCNA), integrated transcriptome analysis, and combining immune-related genes (IRGs) were used to identify core differentially expressed IRGs (DE IRGs). Subsequently, univariate and multivariate Cox regression analyses were utilized to establish an immune-related risk score (IRRS) model for risk stratification for glioma patients. Furthermore, a nomogram was developed for predicting glioma patients’ overall survival (OS). The turquoise module ( ; ) and its genes ( ) were significantly pertinent to glioma progression. Ultimately, multivariate Cox regression analysis constructed an IRRS model based on VEGFA, SOCS3, SPP1, and TGFB2 core DE IRGs, with a C-index of 0.811 (95% CI: 0.786-0.836). Then, Kaplan-Meier (KM) survival curves revealed that patients presenting high risk had a dismal outcome ( ). Also, this IRRS model was found to be an independent prognostic indicator of gliomas’ survival prediction, with HR of 1.89 (95% CI: 1.252-2.85) and 2.17 (95% CI: 1.493-3.14) in the Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) datasets, respectively. We established the IRRS prognostic model, capable of effectively stratifying glioma population, convenient for decision-making in clinical practice.

1 January 2024 in International Journal of Genomics
Verified
Journal Article
Open access
WLWenlin Li
Wenlin Li
HSHaiping Shi
Haiping Shi
JHJimin He
Jimin He
This study investigates the prognostic significance of SH3 and multiple ankyrin repeat domains 2 (SHANK2) gene expression in glioma patients, using data from The Cancer Genome Atlas (TCGA), the Genotype‐Tissue Expression (GTEx) project, and the Gene Expression Omnibus (GEO). Through comprehensive analysis, we found a significant association between higher SHANK2 expression and improved survival outcomes across various glioma subtypes. To further validate the clinical relevance of SHANK2, we conducted cellular experiments involving siRNA‐mediated knockdown of SHANK2 in U87 and A172 glioma cell lines. Quantitative real‐time PCR (qPCR) and Western blot analyses confirmed the successful knockdown of SHANK2, and subsequent MTT assays revealed that silencing SHANK2 significantly promoted glioma cell proliferation. These findings underscore the potential role of SHANK2 as a tumor suppressor in glioma. The study also introduces a multivariate prognostic model incorporating SHANK2, providing a novel perspective on glioma prognosis. While the retrospective nature of the study presents limitations, our results suggest that SHANK2 expression could serve as a valuable biomarker for glioma prognosis and inform future therapeutic strategies.